Literature DB >> 20425537

Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome.

Ricard Cervera1.   

Abstract

The catastrophic antiphospholipid syndrome (APS) is a potentially life-threatening condition, the diagnosis of which requires a high degree of clinical awareness on the part of attending physicians. Patients with APS present with 1) clinical evidence of multiple organ involvement developed over a very short time; 2) histopathologic evidence of multiple small-vessel occlusions; and 3) laboratory confirmation of the presence of antiphospholipid antibodies, usually in high titer. A combination of anticoagulants, corticosteroids, intravenous immunoglobulins, and plasma exchanges is the basic treatment for all patients with this severe condition. Unfortunately, despite current therapies, the mortality rate is still high (around 30%). However, once patients with catastrophic APS have recovered, they usually follow a stable course with continued anticoagulation and few patients present with a relapse of the catastrophic episode.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20425537     DOI: 10.1007/s11926-009-0073-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  34 in total

Review 1.  Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients.

Authors:  R A Asherson; R Cervera; J C Piette; Y Shoenfeld; G Espinosa; M A Petri; E Lim; T C Lau; A Gurjal; A Jedryka-Góral; H Chwalinska-Sadowska; R J Dibner; J Rojas-Rodríguez; M García-Carrasco; J T Grandone; A L Parke; P Barbosa; C Vasconcelos; M Ramos-Casals; J Font; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  2001-11       Impact factor: 1.889

2.  V meeting of the European forum on antiphospholipid antibodies.

Authors:  Ricard Cervera; Josep Font; Angela Tincani; Marie-Claire Boffa
Journal:  Autoimmun Rev       Date:  2006-02-03       Impact factor: 9.754

Review 3.  Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.

Authors:  José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Ronald A Asherson; Mario García-Carrasco; Izaias P da Costa; Danieli C O Andrade; Eduardo F Borba; Alexander Makatsaria; Silvia Bucciarelli; Manuel Ramos-Casals; Josep Font
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

4.  Relapsing catastrophic antiphospholipid syndrome: report of three cases.

Authors:  Ronald A Asherson; Gerard Espinosa; Solomon Menahem; Janet Yinh; Silvia Bucciarelli; Xavier Bosch; Ricard Cervera
Journal:  Semin Arthritis Rheum       Date:  2007-10-30       Impact factor: 5.532

Review 5.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

Review 6.  The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome.

Authors:  Imad Uthman; Ali Shamseddine; Ali Taher
Journal:  Transfus Apher Sci       Date:  2005-08       Impact factor: 1.764

7.  Defibrotide mediated inhibition of serotonin, endothelin-I, thromboxane, and serum induced contraction of canine femoral and pulmonary arterial rings.

Authors:  L H Yang; D A Hoppensteadt; O Iqbal; J Fareed
Journal:  Thromb Res       Date:  1996-11-01       Impact factor: 3.944

8.  The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients.

Authors:  S Bucciarelli; G Espinosa; R A Asherson; R Cervera; G Claver; J A Gómez-Puerta; M Ramos-Casals; M Ingelmo
Journal:  Ann Rheum Dis       Date:  2005-05-26       Impact factor: 19.103

9.  Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.

Authors:  J G Erdozain; G Ruiz-Irastorza; M V Egurbide; C Aguirre
Journal:  Haematologica       Date:  2004-09       Impact factor: 9.941

10.  Long term outcome of catastrophic antiphospholipid syndrome survivors.

Authors:  D Erkan; R A Asherson; G Espinosa; R Cervera; J Font; J-C Piette; M D Lockshin
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

View more
  20 in total

1.  CAPS: a rare acute abdomen.

Authors:  John-Paul Smith; Mark Woodward; Oliver Tunstall; Athimalaipet Ramanan
Journal:  BMJ Case Rep       Date:  2013-07-31

2.  Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1.

Authors:  Melonie L Durkin; Diana Marchese; Marjorie D Robinson; Moti Ramgopal
Journal:  BMJ Case Rep       Date:  2013-09-30

Review 3.  Pediatric antiphospholipid syndrome.

Authors:  Cassyanne L Aguiar; Arzu Soybilgic; Tadej Avcin; Barry L Myones
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

4.  An extraordinary case of recurrent stroke, disseminated thrombosis and endocarditis.

Authors:  Liza Mariam Thomas; Niaz Ahmed Shaikh; Ranjana Pradeep
Journal:  BMJ Case Rep       Date:  2018-06-04

5.  Catastrophic antiphospholipid syndrome presenting with sudden renal failure: The lesson lies in vascular lesions.

Authors:  Muhammed Mubarak
Journal:  J Nephropathol       Date:  2013-04-01

6.  Rare Presentation of Catastrophic Antiphospholipid Syndrome with Myocarditis in Post-partum Period: Case Report and Review of Literature.

Authors:  Bhavana Girish; Shalini Gainder; S C Saha; Darshan Krishnappa
Journal:  J Obstet Gynaecol India       Date:  2017-02-22

Review 7.  Postoperative risk of venous thromboembolism in rheumatic disease patients.

Authors:  Lauren E Wong; Anne R Bass
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 8.  The challenge of bleeding in antiphospholipid antibody-positive patients.

Authors:  Giulia Pazzola; Stéphane Zuily; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 9.  Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease.

Authors:  Cassyanne L Aguiar; Doruk Erkan
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-12       Impact factor: 5.346

Review 10.  Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

Authors:  Malgorzata M Bala; Magdalena Celinska-Lowenhoff; Wojciech Szot; Agnieszka Padjas; Mateusz Kaczmarczyk; Mateusz J Swierz; Anetta Undas
Journal:  Cochrane Database Syst Rev       Date:  2017-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.